08:09 AM EST, 11/18/2024 (MT Newswires) -- Cybin ( CYBN ) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers "sustained relief" through one year.

By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.

Cybin ( CYBN ) said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin ( CYBN ) added.

The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.

Cybin ( CYBN ) shares were up 11% in recent premarket activity.

Price: 12.89, Change: +1.29, Percent Change: +11.12